AW
CPRX

Ankerstar Wealth’s Catalyst Pharmaceutical CPRX Stock Holding History

Ankerstar Wealth’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$817 Buy
33
+15
+83% +$357 ﹤0.01% 490
2025
Q4 		$420 Buy
+18
New +$401 ﹤0.01% 704

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ankerstar Wealth's CPRX Position: Q1 2026 in Review

Ankerstar Wealth increased its Catalyst Pharmaceutical (CPRX) stake by 83% in Q1 2026, buying an estimated $357 and bringing the position to 33 shares worth $817. The position accounts for ﹤0.01% of the portfolio, ranked #490.

Ankerstar Wealth first reported a position in CPRX in Q4 2025 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Ankerstar Wealth held 33 shares of Catalyst Pharmaceutical worth $817 as of Q1 2026.
  • Ankerstar Wealth bought 15 Catalyst Pharmaceutical shares in Q1 2026, an estimated $357.
  • Catalyst Pharmaceutical made up ﹤0.01% of Ankerstar Wealth's portfolio in Q1 2026, its #490 holding.
  • Ankerstar Wealth first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Ankerstar Wealth's 13F filing for Q1 2026, filed 14 May 2026.